These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 24249155)

  • 1. Clinical application of circulating tumor cells in breast cancer.
    Broersen LH; van Pelt GW; Tollenaar RA; Mesker WE
    Cell Oncol (Dordr); 2014 Feb; 37(1):9-15. PubMed ID: 24249155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
    Szostakowska-Rodzos M; Fabisiewicz A; Wakula M; Tabor S; Szafron L; Jagiello-Gruszfeld A; Grzybowska EA
    Sci Rep; 2024 Jun; 14(1):12924. PubMed ID: 38839863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance.
    Sun YF; Yang XR; Zhou J; Qiu SJ; Fan J; Xu Y
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1151-73. PubMed ID: 21681690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay.
    Magbanua MJ; Pugia M; Lee JS; Jabon M; Wang V; Gubens M; Marfurt K; Pence J; Sidhu H; Uzgiris A; Rugo HS; Park JW
    PLoS One; 2015; 10(10):e0141166. PubMed ID: 26496203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
    Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
    BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
    Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment.
    Malara N; Trunzo V; Foresta U; Amodio N; De Vitis S; Roveda L; Fava M; Coluccio M; Macrì R; Di Vito A; Costa N; Mignogna C; Britti D; Palma E; Mollace V
    J Transl Med; 2016 May; 14(1):133. PubMed ID: 27176720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
    Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
    PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
    Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
    World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
    Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients.
    Krawczyk N; Meier-Stiegen F; Banys M; Neubauer H; Ruckhaeberle E; Fehm T
    Biomed Res Int; 2014; 2014():415721. PubMed ID: 24895575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics of Circulating Tumor Cells in Breast Cancer.
    Bao-Caamano A; Rodriguez-Casanova A; Diaz-Lagares A
    Adv Exp Med Biol; 2020; 1220():117-134. PubMed ID: 32304083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Papadaki MA; Stoupis G; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S
    Mol Cancer Ther; 2019 Feb; 18(2):437-447. PubMed ID: 30401696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
    Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
    Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.
    Lu J; Fan T; Zhao Q; Zeng W; Zaslavsky E; Chen JJ; Frohman MA; Golightly MG; Madajewicz S; Chen WT
    Int J Cancer; 2010 Feb; 126(3):669-83. PubMed ID: 19662651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological significance of circulating tumor cells in cancer.
    Masuda T; Hayashi N; Iguchi T; Ito S; Eguchi H; Mimori K
    Mol Oncol; 2016 Mar; 10(3):408-17. PubMed ID: 26899533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.